Johnson & Johnson (NYSE:JNJ) responded with disappointment, claiming its actions were pro-competitive and aimed at ensuring patient safety. The company is weighing an appeal. The landmark verdict ...

A history of consistent dividend increases For a strong and steady performance in a healthcare or medical sector stock, JNJ has fared very well. A $25,000 investment in JNJ in 2005 would be ...

Fintel reports that on May 13, 2025, Leerink Partners downgraded their outlook for Johnson & Johnson (NYSE:JNJ) from Outperform to Market Perform. Analyst Price Forecast Suggests 17.34% Upside As ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other value stocks in Ken Fisher’s portfolio. Trump’s “stupid” tariffs will fail ...

Johnson & Johnson (NYSE:JNJ) stock dropped 7% on Tuesday, April 1, following a significant legal setback. U.S. Bankruptcy Judge Christopher Lopez in Houston rejected the company’s third attempt ...

Johnson & Johnson stock falls more than 7% after a U.S. court rejected its subsidiary’s bankruptcy plan to resolve talc-related lawsuits. The company will now fight the lawsuits in court ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

Johnson & Johnson forms a Death Cross as JNJ stock drops below key moving averages, signaling bearish momentum. Strategic moves in dermatology, including a licensing deal for eczema drug KP-723 ...

My last article on Johnson & Johnson (NYSE:JNJ) was published back in October 2024. That article was entitled “Johnson & Johnson: You Need To Look At This Chart ...